Radius Health Inc (RDUS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Radius Health Inc (RDUS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH139032D
  • |
  • Pages: 60
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Radius Health Inc (Radius Health), formerly NuVios, Inc., is a biopharmaceutical company that develops and commercializes therapeutics for osteoporosis, oncology and endocrine diseases. The company's product includes abaloparatide injection, which is used for the treatment of postmenopausal women with osteoporosis. Its clinical programs include abaloparatide-SC subcutaneous injection for osteoporosis, abaloparatide-TD transdermal patch for osteoporosis, RAD1901 oral for vasomotor symptoms, RAD1901 oral for breast cancer brain metastases, and RAD140 for cachexia or frailty or breast cancer. The company also develops drugs for reproductive disorders. It operates in Waltham, Parsippany, Wayne and Cambridge, the US. Radius Health is headquartered in Waltham, Massachusetts, the US.

Radius Health Inc (RDUS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Radius Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Radius Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Radius Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Radius Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Radius Health Inc, Medical Devices Deals, 2012 to YTD 2018 10

Radius Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Radius Health Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Radius Health Raises USD 43 Million In Venture Financing 12

Partnerships 14

Radius Health Partners with Novartis Pharma for RAD1901 14

Radius Health Enters Into Collaboration Agreement With 3M Drug Delivery Systems 15

Licensing Agreements 16

Radius Health Enters into Licensing Agreement with Duke University 16

Teijin Enters into Licensing Agreement with Radius Health 17

Equity Offering 18

Radius Health Raises USD345 Million in Public Offering of Shares 18

Radius Health Raises USD169 Million in Public Offering of Shares 20

Radius Health Raises USD57.1 Million in Public Offering of Shares 22

Radius Health Raises USD52 Million in IPO of Shares 24

Debt Offering 26

Radius Health Raises USD300 Million in Public Offering of 3% Convertible Notes Due 2024 26

Acquisition 28

Shire May Acquire Radius Health 28

Radius Health Inc-Key Competitors 29

Radius Health Inc-Key Employees 30

Radius Health Inc-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 32

Financial Announcements 32

Nov 01, 2018: Radius Health announces third quarter 2018 operating results and financial guidance for FY 2018 and FY 2019 32

Aug 07, 2018: Radius Health announces second quarter 2018 financial results 35

May 10, 2018: Radius Health Reports First Quarter 2018 Financial and Operating Results and Provides Business Update 38

Mar 01, 2018: Radius Health Reports Fourth Quarter and Full Year 2017 Financial and Operating Results and Provides Business Update 41

Nov 02, 2017: Radius Health Reports Third Quarter 2017 Financial and Operating Results and Provides Business Update 44

May 01, 2017: Radius Health Reports First Quarter 2017 Financial and Operating Results 47

Feb 23, 2017: Radius Health Reports Fourth Quarter and Full Year 2016 Financial and Operating Results 49

Corporate Communications 52

Sep 04, 2018: Radius Health names Dr Charles Morris as Chief Medical Officer 52

Jul 16, 2018: Radius Health appoints Chhaya Shah as senior vice president of technical operations 53

Jul 17, 2017: Radius Health Appoints Jesper Hoiland as President and Chief Executive Officer To Lead The Next Stage Of Growth and Value Creation As A Fully Integrated Commercial Biotech Company 54

May 15, 2017: Radius Health Appoints Pharmaceutical Executive Jose Carmona as Chief Financial Officer 56

Product News 57

03/31/2017: Radius Health Presents Data on Pipeline drug RAD140 at the 2017 American Association for Cancer Research Annual Meeting (AACR) 57

Clinical Trials 58

Sep 29, 2017: Radius Health Initiates Phase 1 Clinical Trial of RAD140 for the Treatment of Hormone Receptor Positive Breast Cancer 58

Mar 31, 2017: Radius Health Presents Preclinical Data on Elacestrant (RAD1901) at the 2017 American Association for Cancer Research Annual Meeting (AACR) 59

Appendix 60

Methodology 60

About GlobalData 60

Contact Us 60

Disclaimer 60

List of Figures

Radius Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Radius Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Radius Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Radius Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Radius Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Radius Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Radius Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Radius Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Radius Health Inc, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Radius Health Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Radius Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Radius Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Radius Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Radius Health Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Radius Health Inc, Medical Devices Deals, 2012 to YTD 2018 10

Radius Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Radius Health Raises USD 43 Million In Venture Financing 12

Radius Health Partners with Novartis Pharma for RAD1901 14

Radius Health Enters Into Collaboration Agreement With 3M Drug Delivery Systems 15

Radius Health Enters into Licensing Agreement with Duke University 16

Teijin Enters into Licensing Agreement with Radius Health 17

Radius Health Raises USD345 Million in Public Offering of Shares 18

Radius Health Raises USD169 Million in Public Offering of Shares 20

Radius Health Raises USD57.1 Million in Public Offering of Shares 22

Radius Health Raises USD52 Million in IPO of Shares 24

Radius Health Raises USD300 Million in Public Offering of 3% Convertible Notes Due 2024 26

Shire May Acquire Radius Health 28

Radius Health Inc, Key Competitors 29

Radius Health Inc, Key Employees 30

Radius Health Inc, Other Locations 31

Radius Health Inc, Subsidiaries 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Radius Health Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17848
Site License
USD 500 INR 35695
Corporate User License
USD 750 INR 53543

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com